Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae type b conjugate vaccine (PRP-OMPC) + hepatitis B vaccine (recombinant) (modified process)
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine developed by Merck Sharp & Dohme (MSD) for the prevention of invasive disease caused by *Haemophilus influenzae* type b (Hib) and hepatitis B virus (HBV) infection in infants. This specific "modified process" version (mpHBV-Hib) was an investigational formulation that incorporated double the amount of phosphate in the aluminum hydroxyphosphate sulfate adjuvant compared to the original licensed Comvax vaccine. This modification was designed to decrease the strength of the antigen-adjuvant binding, which was hypothesized to potentiate the immune response. The vaccine consists of the Hib capsular polysaccharide (polyribosylribitol phosphate, PRP) conjugated to the outer membrane protein complex (OMPC) of *Neisseria meningitidis* serogroup B, and the hepatitis B surface antigen (HBsAg) produced via recombinant yeast technology. Although the original Comvax was FDA-approved, Merck discontinued the product line in 2014.
- Brand names
- Comvax
- Other names
- Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) VaccineHib-HepB vaccinePRP-OMPC-HBsAg
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on haemophilus influenzae type b conjugate vaccine (PRP-OMPC) + hepatitis B vaccine (recombinant) (modified process).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae type b conjugate vaccine (PRP-OMPC) + hepatitis B vaccine (recombinant) (modified process).